Raymond James & Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-20,714
| Closed | -$17.8K | – | 3996 |
|
|
2023
Q4 | $17.8K | Sell |
20,714
-1,209
| -6% | -$1.04K | ﹤0.01% | 3723 |
|
|
2023
Q3 | $23.5K | Sell |
21,923
-310
| -1% | -$332 | ﹤0.01% | 3685 |
|
|
2023
Q2 | $57.6K | Sell |
22,233
-6,343
| -22% | -$16.4K | ﹤0.01% | 3643 |
|
|
2023
Q1 | $117K | Buy |
28,576
+303
| +1% | +$1.24K | ﹤0.01% | 3577 |
|
|
2022
Q4 | $142K | Sell |
28,273
-67,413
| -70% | -$338K | ﹤0.01% | 3522 |
|
|
2022
Q3 | $1.25M | Buy |
95,686
+24,690
| +35% | +$323K | ﹤0.01% | 2254 |
|
|
2022
Q2 | $910K | Buy |
70,996
+8,108
| +13% | +$104K | ﹤0.01% | 2505 |
|
|
2022
Q1 | $959K | Buy |
+62,888
| New | +$959K | ﹤0.01% | 2616 |
|
|
2021
Q2 | – | Sell |
-80,692
| Closed | -$2.35M | – | 4017 |
|
|
2021
Q1 | $2.35M | Buy |
80,692
+18,817
| +30% | +$547K | ﹤0.01% | 1907 |
|
|
2020
Q4 | $1.88M | Sell |
61,875
-2,407
| -4% | -$72.9K | ﹤0.01% | 1920 |
|
|
2020
Q3 | $1.02M | Buy |
64,282
+6,388
| +11% | +$102K | ﹤0.01% | 2157 |
|
|
2020
Q2 | $1.14M | Buy |
+57,894
| New | +$1.14M | ﹤0.01% | 2063 |
|